There is no website visitor data available for this stock.
---
NHWK FAQ
What was NightHawk Biosciences’s price range in the past 12 months?
NightHawk Biosciences lowest stock price was $0.50 and its highest was $1.90 in the past 12 months.
What is NightHawk Biosciences’s market cap?
Currently, no data Available
When is NightHawk Biosciences’s upcoming earnings report date?
NightHawk Biosciences’s upcoming earnings report date is Nov 13, 2023 which is in 50 days.
How were NightHawk Biosciences’s earnings last quarter?
NightHawk Biosciences released its earnings results on Aug 14, 2023. The company reported -$0.53 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.53.
NightHawk Biosciences does not currently pay dividends.
What is NightHawk Biosciences’s EPS estimate?
NightHawk Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NightHawk Biosciences have?
NightHawk Biosciences has 26,081,890 shares outstanding.
What happened to NightHawk Biosciences’s price movement after its last earnings report?
NightHawk Biosciences reported an EPS of -$0.53 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of NightHawk Biosciences?
Currently, no hedge funds are holding shares in NHWK
This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.